Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules

Gaetana Di Fede, Giuseppe Bronte, Giovam Battista Rini, Antonio Russo, Michele Caraglia, Daniele Santini, Daniele Santini, Giovanni Sortino, Sergio Rizzo

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-related pathways are described, most relevant clinical findings about target therapy applications are exposed and the clinical impact of predictive factors of efficacy and toxicity are discussed.
Original languageEnglish
Pages (from-to)944-55-
Number of pages12
JournalCurrent Drug Metabolism
Volume12
Publication statusPublished - 2011

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules'. Together they form a unique fingerprint.

Cite this